William J. John

5
h-index
5
Publications
2,669
Citations

Publications

5 shown

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0....

2013 Journal of Clinical Oncology 626 citations

Frequent Co-Authors

Researcher Info

h-index
5
Publications
5
Citations
2,669
Institution
Eli Lilly (United States)

External Links

Impact Metrics

h-index 5

h-index: Number of publications with at least h citations each.

Academic Output Over Time